leisure time -WSS

leisure time

author：hotspot 2025-09-27 10:04:57 - browse：596

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Maker of FluMist seeks to allow at

explore

WSS

Meta's Zuckerberg and Chan on track to put $50 billion into science

The FDA weighs the risks of candy

Cassava reveals details — and problems — with Alzheimer's study

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

The pink breast cancer awareness ribbon needs a redesign

Paying for Covid pills will soon shift to insurers

focus

leisure time

entertainment

Medicare proposal to cover medical devices draws a mixed reaction

Diversifying clinical trials isn't enough to close racial gaps: study

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

23andMe had bad news about my health. I wish a person had delivered it

Readout Newsletter: What happened with Sarepta's Duchenne data

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Biden's order seeks to regulate AI risk without stifling innovation

focus

Medtronic CEO on promising devices for diabetes, hypertension

Diversifying clinical trials isn't enough to close racial gaps: study

Readout Newsletter: What happened with Sarepta's Duchenne data

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Cassava reveals details — and problems — with Alzheimer's study

entertainment

Wikipedia

explore

knowledge